DLX5 and ovarian carcinoma: DLX5 can promote ovarian cancer cell proliferation by enhancing the IRS-2-AKT pathway; moreover, in osteosarcoma, DLX5 can activate the NOTCH signaling pathway to promote tumor progression [17].